Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium-based contrast agent presented as a 0.5 mmol/mL injectable solution for intravenous use. It enhances magnetic resonance imaging of specific organs and vascular structures in patients undergoing diagnostic examinations.

GNH USA supplies Multihance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Multihance is used as a gadolinium‑based contrast agent to improve magnetic resonance imaging of several organ systems.

- Central nervous system: enhances visualization of brain and spinal cord structures during MRI. - Liver: provides high‑contrast images of hepatic tissue and lesions. - Cardiovascular system and angiography: improves delineation of blood vessels and cardiac anatomy in MRI studies.

Multihance may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild, usually resolves without intervention. - Headache: transient discomfort after injection. - Injection site discomfort: mild pain or burning sensation. - Warmth sensation: feeling of heat in the body during administration. - Dizziness: brief episodes of light‑headedness. - Metallic taste: temporary alteration of taste.

Serious or Rare Side Effects: - Allergic reaction or anaphylaxis: severe hypersensitivity requiring immediate medical attention. - Nephrogenic systemic fibrosis (NSF): rare fibrotic disorder in patients with severe renal impairment. - Severe hypotension: sudden drop in blood pressure. - Arrhythmia: irregular heart rhythm. - Pulmonary edema: fluid accumulation in the lungs. - Severe skin rash: extensive dermatologic reaction.

Prior to using Multihance, clinicians should assess patient‑specific risk factors and follow handling guidelines.

- Renal function assessment: evaluate kidney function before administration, especially in patients with GFR <30 mL/min/1.73 m². - Pregnancy: use only if clearly needed, as it is classified as Category C. - Breastfeeding: consider potential exposure to the infant; weigh benefits against risks. - History of hypersensitivity: avoid or use with caution in patients with prior reactions to gadolinium agents. - Concurrent nephrotoxic drugs: monitor renal status closely when used with other nephrotoxic medications. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Multihance can interact with other agents that affect renal function or chelation processes.

Major Interactions (Avoid): - Severe renal impairment: increased risk of nephrogenic systemic fibrosis; avoid use. - High‑dose iodinated contrast within 24 h: may compound renal toxicity. - Chelating agents (e.g., deferoxamine): may reduce the efficacy of gadolinium binding.

Moderate Interactions (Monitor Closely): - Loop diuretics: may alter renal clearance of the contrast. - Nephrotoxic antibiotics (e.g., aminoglycosides): monitor kidney function during concurrent therapy.